<DOC>
	<DOCNO>NCT02802423</DOCNO>
	<brief_summary>The primary purpose study determine safety recommend dose level ( RDL ) BLEX 404 Oral Liquid combine Docetaxel monotherapy 21-day schedule . The secondary purpose ass efficacy safety BLEX 404 Oral Liquid combine Docetaxel monotherapy .</brief_summary>
	<brief_title>A Phase I/II , Open Label Study Evaluate Safety Efficacy BLEX 404 Oral Liquid Combined With Docetaxel Monotherapy Patients With Advanced/Metastatic Triple Negative Breast Cancer ( TNBC ) .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>1 . Females age 20 70 year old time sign ICF . 2 . Patients histologically pathologically diagnose advanced/metastatic triple negative ( ER , PR , HER2negative ) breast cancer . 1 . ER = &lt; 10 % immunohistochemistry ( IHC ) tumor stain ; 2 . PR = &lt; 10 % IHC tumor staining ; 3 . HER2negative define one following : 0 1+ IHC , 2+ IHC fluorescence situ hybridization ( FISH ) negative ( ratio &lt; 2.0 ) . 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 . 4 . Adequate hematologic function define : absolute neutrophil count ( ANC ) great equal 2,000/μL ; platelet count great equal 100,000/μL ; hemoglobin must great equal 10 g/dL ( corrected growth factor transfusion ) . 5 . Adequate hepatic function define : serum bilirubin less equal 1.5fold upper limit normal ( ULN ) ; aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase ( ALP ) less equal 3fold ULN . 6 . Adequate renal function : serum creatinine less equal 1.3 mg/dL calculate creatinine clearance great equal 60 mL/minute accord Cockcroft Gault formula . 7 . Women must either nonchild bear potential , woman childbearing potential agree use effective highly contraceptive method contraceptive implant , exception hormonal contraception ( estrogen/progesterone ) , time Screening Visit 30 day study drug discontinuation . 8 . Planning receive Docetaxel monotherapy . 9 . Willing able comply aspect treatment protocol . 10 . Provide write informed consent . 1 . Patient brain metastasis . 2 . Patient autoimmune disease require systemic steroid immunosuppression agent . 3 . Current enrollment another clinical study use investigational drug device within past 28 day precede informed consent . 4 . Patients follow treatment prior Docetaxel monotherapy : chemotherapy , immunotherapy , biologic systemic anticancer therapy within 21 day study entry ( 42 day mitomycin nitrosoureas ) ; prior taxanes ; radiation therapy within 28 day ( 3 month bone marrow exposure 20 % ) ; hormonal therapy within 4 week . 5 . Known history human immunodeficiency virus ( HIV ) infection . 6 . Existing anticancer treatmentrelated toxicity Grades great equal 2 ( except alopecia neuropathy ) accord Common Terminology Criteria Adverse Events ( CTCAE v4.03 ) . 7 . Patients Grade &gt; 2 neuropathy . 8 . Patient active infection require systemic therapy . 9 . History concomitant medical condition infectious disease , opinion investigator , would compromise subject 's ability safely complete study . 10 . Clinically significant electrocardiogram ( ECG ) abnormality , include mark baseline prolong QT/QTc ( [ QT interval/corrected QT interval ] . 11 . Ascertained hypersensitivity component investigational product use study . 12 . Uncontrolled nausea vomit symptom would prevent ability comply daily BLEX 404 Oral Liquid treatment . 13 . Judged applicable study investigator difficulty followup observation , psychiatric disorder , serious diseases/medical history .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>TNBC</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Triple negative</keyword>
</DOC>